Efficacy and security of tumor vaccines for hepatocellular carcinoma: a systemic review and meta-analysis of the last 2 decades

Baradaran Noveiry B, Hirbod-Mobarakeh A, Khalili N, Hourshad N, Greten TF, Abou-Alfa GK et al (2017) Specific immunotherapy in hepatocellular cancer: A systematic review. J Gastroenterol Hepatol 32(2):339–351. https://doi.org/10.1111/jgh.13449

Article  PubMed  Google Scholar 

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424. https://doi.org/10.3322/caac.21492

Article  PubMed  Google Scholar 

Butterfield LH (2015) Cancer Vaccines Bmj 350:h988. https://doi.org/10.1136/bmj.h988

Article  PubMed  Google Scholar 

Butterfield LH, Ribas A, Dissette VB, Lee Y, Jin QY, De La Rocha P et al (2006) A phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four α-fetoprotein peptides. Clin Cancer Res 12(9):2817–2825. https://doi.org/10.1158/1078-0432.CCR-05-2856

Article  CAS  PubMed  Google Scholar 

Chen C, Ma YH, Zhang YT, Zhang F, Zhou N, Wang X et al (2018) Effect of dendritic cell-based immunotherapy on hepatocellular carcinoma: a systematic review and meta-analysis. Cytotherapy 20(8):975–989. https://doi.org/10.1016/j.jcyt.2018.06.002

Article  CAS  PubMed  Google Scholar 

Collin M, Bigley V (2018) Human dendritic cell subsets: an update. Immunology 154(1):3–20. https://doi.org/10.1111/imm.12888

Article  CAS  PubMed  PubMed Central  Google Scholar 

El Ansary M, Mogawer S, Abd Elhamid S, Alwakil S, Aboelkasem F, El Sabaawy H et al (2013) Immunotherapy by autologous dendritic cell vaccine in patients with advanced HCC. J Cancer Res Clin Oncol 139(1):39–48. https://doi.org/10.1007/s00432-012-1298-8

Article  CAS  PubMed  Google Scholar 

Greten TF, Forner A, Korangy F, N’Kontchou G, Barget N, Ayuso C et al (2010) A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma. BMC Cancer. https://doi.org/10.1186/1471-2407-10-209

Article  PubMed  PubMed Central  Google Scholar 

Guo W, Liu L, Wu D (2014) Dendritic cell-cytokine induced killer cell immunotherapy combined with transcatheter arterial chemoembolization for hepatocellular carcinoma: safety and efficacy. Nan Fang Yi Ke Da Xue Xue Bao J Southern Med Univ 34(5):674–678

Google Scholar 

He G, Zheng C, Huo H, Zhang H, Zhu Z, Li J et al (2016) TACE combined with dendritic cells and cytokine-induced killer cells in the treatment of hepatocellular carcinoma: a meta-analysis. Int Immunopharmacol 40:436–442. https://doi.org/10.1016/j.intimp.2016.09.015

Article  CAS  PubMed  Google Scholar 

He Y, Guo Y, Chen J, Hu X, Li X, Kong Y et al (2018) Multiple Antigen Stimulating Cellular Therapy (MASCT) for hepatocellular carcinoma after curative treatment: A retrospective study. J Cancer 9(8):1385–1393. https://doi.org/10.7150/jca.23725

Article  CAS  PubMed  PubMed Central  Google Scholar 

Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD et al (2011) The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 343:d5928. https://doi.org/10.1136/bmj.d5928

Article  PubMed  PubMed Central  Google Scholar 

Huang J, Hu X, Chen X, Zhang M, Chen F, Guo Y (2016) The safety of multiple antigen stimulating cellular therapy in treating patients with hepatocellular carcinoma. Chin J Cancer Biother 23(1):11–16. https://doi.org/10.3872/j.issn.1007-385X.2016.01.002

Article  CAS  Google Scholar 

Ikeda M, Okusaka T, Ohno I, Mitsunaga S, Kondo S, Ueno H et al (2021) Phase i studies of peptide vaccine cocktails derived from GPC3, WDRPUH and NEIL3 for advanced hepatocellular carcinoma. Immunotherapy 13(5):371–385. https://doi.org/10.2217/imt-2020-0278

Article  CAS  PubMed  Google Scholar 

Keenan BP, Jaffee EM (2012) Whole cell vaccines–past progress and future strategies. Semin Oncol 39(3):276–286. https://doi.org/10.1053/j.seminoncol.2012.02.007

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kiani FK, Izadi S, Dezfouli EA, Ebrahimi F, Mohammadi M, Chalajour H et al (2021) Simultaneous silencing of A2aR and PD-1 as immune checkpoints by siRNA-loaded nanoparticles enhances the immunotherapeutic potential of dendritic cell vaccine in tumor experimental models. Life Sci. https://doi.org/10.1016/j.lfs.2021.120166

Article  Google Scholar 

Kou X, Huang Y, Yuan Z, Wu M, Qian Q (2015) Efficacy of the combined therapy with autologous dendritic cells-cytokine induced killer cells and percutaneous microwave coagulation for hepatocellular carcinoma. Chin J Cancer Biother 22(4):509–513. https://doi.org/10.3872/j.issn.1007-385X.2015.04.018

Article  CAS  Google Scholar 

Kuang M, Peng BG, Lu MD, Liang LJ, Huang JF, He Q et al (2004) Phase II randomized trial of autologous formalin-fixed tumor vaccine for postsurgical recurrence of hepatocellular carcinoma. Clin Cancer Res 10(5):1574–1579. https://doi.org/10.1158/1078-0432.ccr-03-0071

Article  CAS  PubMed  Google Scholar 

Lee WC, Wang HC, Hung CF, Huang PF, Lia CR, Chen MF (2005) Vaccination of advanced hepatocellular carcinoma patients with tumor lysate-pulsed dendritic cells: A clinical trial. J Immunother 28(5):496–504. https://doi.org/10.1097/01.cji.0000171291.72039.e2

Article  PubMed  Google Scholar 

Lee J-H, Lee Y, Lee M, Heo MK, Song J-S, Kim K-H et al (2015) A phase I/IIa study of adjuvant immunotherapy with tumour antigen-pulsed dendritic cells in patients with hepatocellular carcinoma. Br J Cancer 113(12):1666–1676. https://doi.org/10.1038/bjc.2015.430

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lee J-H, Tak WY, Lee Y, Heo M-K, Song J-S, Kim H-Y et al (2017) Adjuvant immunotherapy with autologous dendritic cells for hepatocellular carcinoma, randomized phase II study. Oncoimmunology. https://doi.org/10.1080/2162402x.2017.1328335

Article  PubMed  PubMed Central  Google Scholar 

Liu H, Chen L, Peng Y, Yu S, Liu J, Wu L et al (2018) Dendritic cells loaded with tumor derived exosomes for cancer immunotherapy. Oncotarget 9(2):2887–2894. https://doi.org/10.18632/oncotarget.20812

Article  PubMed  Google Scholar 

Liu Z, Jiang Y, Yuan H, Fang Q, Cai N, Suo C et al (2019) The trends in incidence of primary liver cancer caused by specific etiologies: results from the Global Burden of Disease Study 2016 and implications for liver cancer prevention. J Hepatol 70(4):674–683. https://doi.org/10.1016/j.jhep.2018.12.001

Article  PubMed  Google Scholar 

Maeda Y, Yoshimura K, Matsui H, Shindo Y, Tamesa T, Tokumitsu Y et al (2015) Dendritic cells transfected with heat-shock protein 70 messenger RNA for patients with hepatitis C virus-related hepatocellular carcinoma: a phase 1 dose escalation clinical trial. Cancer Immunol Immunother 64(8):1047–1056. https://doi.org/10.1007/s00262-015-1709-1

Article  CAS  PubMed  Google Scholar 

Malonis RJ, Lai JR, Vergnolle O (2020) Peptide-based vaccines: current progress and future challenges. Chem Rev 120(6):3210–3229. https://doi.org/10.1021/acs.chemrev.9b00472

Article  CAS  PubMed  Google Scholar 

Matsui HM, Hazama S, Nakajima M, Xu M, Matsukuma S, Tokumitsu Y et al (2021) Novel adjuvant dendritic cell therapy with transfection of heat-shock protein 70 messenger RNA for patients with hepatocellular carcinoma: a phase I/II prospective randomized controlled clinical trial. Cancer Immunol Immunother 70(4):945–957. https://doi.org/10.1007/s00262-020-02737-y

Article  CAS  PubMed  Google Scholar 

Mizukoshi E, Nakagawa H, Kitahara M, Yamashita T, Arai K, Sunagozaka H et al (2015) Phase I trial of multidrug resistance-associated protein 3-derived peptide in patients with hepatocellular carcinoma. Cancer Lett 369(1):242–249. https://doi.org/10.1016/j.canlet.2015.08.020

Article  CAS  PubMed  Google Scholar 

Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6(7):e1000097. https://doi.org/10.1371/journal.pmed.1000097

Article  PubMed  PubMed Central  Google Scholar 

Nakagawa H, Mizukoshi E, Kobayashi E, Tamai T, Hamana H, Ozawa T et al (2017) Association between high-avidity T-cell receptors, induced by α-fetoprotein-derived peptides, and anti-tumor effects in patients with hepatocellular carcinoma. Gastroenterology 152(6):1395-1406.e1310. https://doi.org/10.1053/j.gastro.2017.02.001

Article  CAS  PubMed  Google Scholar 

Parks AL, McWhirter RM, Evason K, Kelley RK (2015) Cases of spontaneous tumor regression in hepatobiliary cancers: implications for immunotherapy? J Gastrointest Cancer 46(2):161–165. https://doi.org/10.1007/s12029-015-9690-7

Article  PubMed  PubMed Central  Google Scholar 

Peng BG, Liu SQ, Kuang M, He Q, Totsuka S, Huang L et al (2002) Autologous fixed tumor vaccine: A formulation with cytokine-microparticles for protective immunity against recurrence of human hepatocellular carcinoma. Jpn J Cancer Res 93(4):363–368. https://doi.org/10.1111/j.1349-7006.2002.tb01265.x

Article  CAS  PubMed  PubMed Central  Google Scholar 

Peng B-G, Liang L-J, He Q, Kuang M, Lia J-M, Lu M-D et al (2005) Tumor vaccine against recurrence of hepatocellular carcinoma. World J Gastroenterol 11(5):700–704. https://doi.org/10.3748/wjg.v11.i5.700

Article  PubMed  PubMed Central  Google Scholar 

Rosenberg SA, Yang JC, Restifo NP (2004) Cancer immunotherapy: moving beyond current vaccines. Nat Med 10(9):909–915. https://doi.org/10.1038/nm1100

Article  CAS  PubMed  PubMed Central  Google Scholar 

Santos PM, Butterfield LH (2018) Dendritic cell-based cancer vaccines. J Immunol 200(2):443–449. https://doi.org/10.4049/jimmunol.1701024

Article  CAS  PubMed  Google Scholar 

Sawada Y, Yoshikawa T, Nobuoka D, Shirakawa H, Kuronuma T, Motomura Y et al (2012) Phase I trial of a glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma: Immunologic evidence and potential for improving overall survival. Clin Cancer Res 18(13):3686–3696. https://doi.org/10.1158/1078-0432.CCR-11-3044

留言 (0)

沒有登入
gif